Oncolytics Biotech Past Earnings Performance
Past criteria checks 0/6
Oncolytics Biotech's earnings have been declining at an average annual rate of -0.3%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
-0.3%
Earnings growth rate
25.1%
EPS growth rate
| Biotechs Industry Growth | 51.1% |
| Revenue growth rate | n/a |
| Return on equity | -305.2% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully
Feb 23
Is Oncolytics Biotech (TSE:ONC) In A Good Position To Deliver On Growth Plans?
Nov 10We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully
Jul 07Is Oncolytics Biotech (TSE:ONC) In A Good Position To Deliver On Growth Plans?
Mar 24Is Oncolytics Biotech (TSE:ONC) In A Good Position To Invest In Growth?
Dec 09We're Keeping An Eye On Oncolytics Biotech's (TSE:ONC) Cash Burn Rate
Aug 25Here's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn Situation
May 12We Think Oncolytics Biotech (TSE:ONC) Can Afford To Drive Business Growth
Dec 02We Think Oncolytics Biotech (TSE:ONC) Can Afford To Drive Business Growth
Aug 05Companies Like Oncolytics Biotech (TSE:ONC) Are In A Position To Invest In Growth
Apr 15We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully
Dec 31Revenue & Expenses Breakdown
How Oncolytics Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -28 | 14 | 22 |
| 30 Jun 24 | 0 | -28 | 16 | 21 |
| 31 Mar 24 | 0 | -28 | 16 | 20 |
| 31 Dec 23 | 0 | -28 | 16 | 18 |
| 30 Sep 23 | 0 | -32 | 16 | 18 |
| 30 Jun 23 | 0 | -27 | 13 | 16 |
| 31 Mar 23 | 0 | -24 | 12 | 15 |
| 31 Dec 22 | 0 | -25 | 11 | 15 |
| 30 Sep 22 | 0 | -24 | 12 | 14 |
| 30 Jun 22 | 0 | -24 | 12 | 20 |
| 31 Mar 22 | 0 | -27 | 13 | 14 |
| 31 Dec 21 | 0 | -26 | 13 | 13 |
| 30 Sep 21 | 0 | -28 | 14 | 13 |
| 30 Jun 21 | 0 | -30 | 13 | 8 |
| 31 Mar 21 | 0 | -29 | 13 | 13 |
| 31 Dec 20 | 0 | -23 | 13 | 13 |
| 30 Sep 20 | 0 | -33 | 13 | 12 |
| 30 Jun 20 | 0 | -29 | 12 | 9 |
| 31 Mar 20 | 0 | -28 | 11 | 10 |
| 31 Dec 19 | 0 | -33 | 9 | 11 |
| 30 Sep 19 | 0 | -19 | 8 | 11 |
| 30 Jun 19 | 0 | -18 | 7 | 11 |
| 31 Mar 19 | 0 | -17 | 7 | 10 |
| 31 Dec 18 | 0 | -17 | 7 | 10 |
| 30 Sep 18 | 0 | -17 | 7 | 9 |
| 30 Jun 18 | 0 | -17 | 7 | 8 |
| 31 Mar 18 | 0 | -17 | 7 | 9 |
| 31 Dec 17 | 0 | -16 | 6 | 9 |
| 30 Sep 17 | 0 | -16 | 6 | 9 |
| 30 Jun 17 | 0 | -16 | 6 | 9 |
| 31 Mar 17 | 0 | -15 | 5 | 8 |
| 31 Dec 16 | 0 | -15 | 6 | 8 |
| 30 Sep 16 | 0 | -13 | 5 | 8 |
| 30 Jun 16 | 0 | -13 | 5 | 8 |
| 31 Mar 16 | 0 | -14 | 5 | 9 |
| 31 Dec 15 | 0 | -14 | 5 | 9 |
| 30 Sep 15 | 0 | -14 | 5 | 9 |
| 30 Jun 15 | 0 | -16 | 5 | 11 |
| 31 Mar 15 | 0 | -17 | 5 | 12 |
| 31 Dec 14 | 0 | -19 | 5 | 14 |
| 30 Sep 14 | 0 | -21 | 5 | 16 |
| 30 Jun 14 | 0 | -22 | 5 | 17 |
| 31 Mar 14 | 0 | -22 | 5 | 18 |
Quality Earnings: ONC is currently unprofitable.
Growing Profit Margin: ONC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ONC is unprofitable, and losses have increased over the past 5 years at a rate of 0.3% per year.
Accelerating Growth: Unable to compare ONC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ONC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: ONC has a negative Return on Equity (-305.2%), as it is currently unprofitable.